Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Plant Journal : for Cell and Molecular Biology|July 4, 2007
Salt tolerance (STO), a stress-related protein, has a major role in light signallingMartin Indorf, Julio Cordero, Gunther Neuhaus, et al.
BMC Cancer|April 19, 2014
Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trialKarin Potthoff, Gregor Habl, Thomas Bruckner, et al.
Plant Physiology|June 21, 2011
Nuclear localization and interaction with COP1 are required for STO/BBX24 function during photomorphogenesisHuili Yan, Katrin Marquardt, Martin Indorf, et al.
BMC Cancer|July 27, 2017
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)Thomas Decker, Friedrich Overkamp, Siegfried Rösel, et al.
BMC Cancer|April 8, 2020
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancerThomas Decker, Ulrike Söling, Antje Hahn, et al.
Breast Care (Basel, Switzerland)|February 22, 2024
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line SettingThomas Decker, Matthias Zaiss, Dunja Klein, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Journal of Cancer Research and Clinical Oncology|February 16, 2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin careCarl Christoph Schimanski, Frank Staib, Thomas Göhler, et al.
European Urology|May 9, 2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell CancerChristian Eichelberg, Walter L Vervenne, Maria De Santis, et al.
Pageof 1